CDK4 and neoplasm: As an example, we assigned to “targeted therapy” to both bevacizumab, VEGF-targeted therapy (component of mBC therapy affecting the tumor angiogenesis) and palbociclib, inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) involved are the downstream of signaling pathways which lead to cellular proliferation).